Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Market Wrap: Zimmer's Big Deal; Durable Orders Up...and Away!; UPS Slips on Winter Chill
- After-Hours Stock Movers 4/24: (CLH) (MKTO) (BIDU) Higher; (CAMP) (P) (CLF) Lower (more...)
- Microsoft Corp. (MSFT) Tops Q3 EPS by 5c
- Amazon.com, Inc. (AMZN) Reports In-Line Q1 EPS, Sales Beat
- Baidu.com (BIDU) Tops Q1 EPS by 25c; Issues Q2 Revs Outlook
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- Eteplirsen Approval Could Add $500M/Yr. to Sarepta Therapeutics (SRPT) Top Line - Barron's
- Zerenex Costs Savings, Differentiation Highlighted; PDUFA Date Still in Focus (KERX) - Roth Capital
- Alexion Pharmaceuticals, Inc. (ALXN) Initiates Soliris Safety, Efficacy Trial
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!